SOURCE: Atossa Genetics Inc
SEATTLE, WA--(Marketwired - Aug 22, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company™, will visit the NASDAQ MarketSite in Times Square to celebrate its listing on the NASDAQ Stock Market, which occurred on November 8, 2012. In honor of the occasion, Dr. Steven C. Quay, Chairman, President and Chief Executive Officer, will ring the closing Bell.
NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast Studio
Monday, August 26nd, 2013 -- 3:45 pm to 4:00 pm ET
A live webcast of the NASDAQ Closing Bell will be available at:
Dr. Steven C. Quay, Chairman, CEO and President, stated, "As a leading molecular diagnostics company, we offer unique innovative solutions for breast health, including our ForeCYTE Breast Health Test, an early warning system for precancerous abnormalities that may lead to breast cancer. We are pleased to have a listing on NASDAQ as it provides an efficient platform to grow our business."
Dr. Quay continued, "We look forward to an exciting event at Nasdaq for friends and family of Atossa Genetics, including Ms. Sidney Powell, founder of Sidney Powell, P.C., a law firm dedicated to federal appellate practice, and Mr. Steven Bernstein, Director of the soon-to-be-released feature film Decoding Annie Parker, which tells the story of Annie Parker, a breast cancer victim."
About the ForeCYTE Breast Health Test
The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office. A small sample of fluid, aspirated from the nipple of each breast with the Company's modified breast pump, can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test and the test is painless.
Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes.
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, the National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.
The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.
For additional information on Atossa, please visit www.atossagenetics.com. For additional information on the ForeCYTE test and the National Reference Laboratory for Breast Health, please visit www.nrlbh.com.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.